Cancer — NK cell therapy: what the evidence shows

If you’re reading this, you’re probably somewhere between “my oncologist mentioned there’s nothing standard left” and “someone sent me a link.”

Both are real places to be, and they call for different things. This page is built to be useful from either — and to be useful if the answer turns out to be no.

One thing worth saying now: nothing here asks you to stop or change anything your oncologist is doing. If a provider ever suggests replacing standard treatment with something like this, that is the moment to leave.

Most pages in this field describe one therapy as though it were the only choice. It isn’t. Here are the four real ones, side by side.

	Standard care only	Standard care and explore this	This instead of standard care	Wait and revisit
What it is	Continue what your oncology team recommends	Continue standard care; a physician separately assesses whether this is appropriate	Decline or interrupt standard treatment for this	Do nothing now; revisit at a defined point
Who tends to consider it	Most people, most of the time	People with a confirmed diagnosis who want to know if they’re a candidate	—	People who need time, or whose situation may change
What the evidence says	Strongest evidence of anything on this page	Small early trials; no comparison to standard care	No evidence supports this. We will not help arrange it	Waiting has costs that depend entirely on your disease
Certainty of that statement	High	Low	High	Not applicable — depends on your case

These four are not equally studied, and the table does not pretend they are. The certainty label under each is doing real work: “low” next to column two is not a formality.

What this is. NK cells — “natural killer” cells — are part of the immune system you already have. They are unusual in one specific way: most immune cells have to be shown a target first, learn it, and then act. NK cells act on a target they have never seen before. They read the surface of a cell for signs that something is wrong — signals a healthy cell displays and a damaged or infected one loses — and respond to their absence.

What the therapy is trying to do. Cancer cells survive partly by making themselves hard for the immune system to see, and by wearing that system down. NK cell therapy takes those cells, grows them outside the body in large numbers, and returns them — the idea being that a fresh, expanded population can do a job the person’s own cells have become too few or too tired to do.

Why researchers became interested. Two things. NK cells do not need to be matched to the patient the way T cells do, so they can be prepared from a healthy donor in advance rather than made for one person. And in the trials so far they have not caused graft-versus-host disease, the complication that makes donor T cells dangerous.

Why someone might reasonably discuss it with a physician. Because it is a real area of clinical research with published human trials — and because whether any of it applies to a particular diagnosis, at a particular stage, is exactly the kind of question a physician answers and a page cannot.

The clearest published result comes from a trial of engineered NK cells in lymphoid cancers, published in Nature Medicine in 2024. About 49 of every 100 responded; about 68 of every 100 were alive at one year.

Notably, none developed cytokine release syndrome, neurotoxicity, or graft- versus-host disease — the serious complications that limit some other cell therapies.

Certainty: low. These numbers may improve or worsen substantially as larger trials report. And they are averages across a group of people: improvements seen in clinical trials cannot predict what will happen to any one patient.

Three things it does not show, stated plainly.

It does not show durability. In that same trial, about 32 of every 100 were free of progression at one year. Most people progressed. A response is not a cure, and short responses are common.

It does not show benefit everywhere. A separate trial in children with acute myeloid leukemia produced no reduction in relapse and no improvement in survival — the trial and its design are in the reference block below.

It does not show a finished field. Across solid tumors, 125 trials have been registered since 2011, and the great majority are early phase. Two companies scaled back their cancer programmes in 2023 and 2024 while keeping NK work in phase 1.

Certainty: high that these three statements are accurate today.

Short version: approval is applied for, granted per country, and per indication — and no company has completed that process anywhere for NK cell therapy.

That is different from “it doesn’t work,” and different from “it works.” It means the question hasn’t been settled by the system that settles it.

→ The full explanation, including what actually protects you →

Understanding the numbers is not the same as knowing what to do with them. The things that usually decide it:

How you weigh a small chance. A treatment that helps about half of a small group, briefly, means different things to different people. Neither reading is wrong.

What weeks away from home cost you. This involves travel, time, and being away from your own medical team.

What your family thinks. Most people don’t decide this alone, and pretending otherwise makes it harder.

Your tolerance for not knowing. Some people find “we don’t have the data” unbearable. Some find it clarifying. Knowing which you are is useful before you go further.

Said before you ask, because you shouldn’t have to.

• You’re being told to stop or delay standard treatment. No legitimate provider will suggest this.
• You don’t have a confirmed diagnosis or accessible medical records. A physician cannot assess a case without them.
• You’re in an acute crisis — uncontrolled infection, unstable condition. This is not for that situation.
• You are not willing to share your medical records. A responsible review cannot be carried out without them.
• If you are looking for certainty rather than an independent medical opinion, this process may not meet your expectations.
• The cost would take something you cannot afford to lose.

Deciding to revisit this in a few weeks is a decision, not a failure.

Take these to any provider, including this one. A provider who can answer them is telling you something; a provider who answers with the word advanced is telling you something else.

1. Where was this product made, and under what regulatory registration?
2. What testing is done on each batch before it’s released?
3. What exactly is in the vial — cell type, count, viability after thawing?
4. Is there a potency assay, and what does it measure?
5. What has been published on this preparation, not on the category?
6. What would make you tell me I’m not a candidate?
7. What happens if it doesn’t work?

Print this page and take it with you.

About half of health searches are made on behalf of another person. If that’s you, a few things.

You don’t have to bring them a conclusion. Bringing them the questions is more useful, and less exhausting for both of you.

Print section 9 and section 2. They travel better on paper than as a link, and they work in a room with a doctor in it.

You can start the review on their behalf — but their consent is required before any medical record is shared and before the review goes any further. That step is in the process, not a surprise at the end.

Consider what you need. Caregivers researching at 2 a.m. are a documented phenomenon. It’s worth telling someone that you’re doing it.

If you request a review:

1. You send records through a secure upload link — not by email or text. What the physician needs for this review lists exactly what to gather.
2. An independent physician reviews the case. Some patients are advised that this treatment is not appropriate for their situation.
3. If they consider it appropriate, they speak with you directly. They explain any applicable fees at that point — Human Paths does not set, publish, collect or process payment for healthcare services.
4. You decide. Nothing before this point commits you to anything.

The review begins once a sufficiently complete set of records has been received. You will be told how it is progressing.

What the trip usually looks like. Most people travel once — occasionally a second visit is needed, depending on the treatment plan — and stay about 10 to 14 days. The treating physician confirms the final schedule after reviewing your case.

The request form is linked from the home page, deliberately not from here: reading the evidence and asking for a review are two separate steps.